sadat
colleagu
report
two
sibl
rare
genet
diseas
type
ii
congenit
disord
glycosyl
cdgiib
caus
genet
defect
gene
encod
nlink
glycan
process
enzym
mannosyloligosaccharid
glucosidas
mog
also
known
endoplasm
reticulum
er
glucosidas
unlik
previous
report
case
cdgiib
patient
die
age
day
two
sibl
year
old
present
multipl
neurolog
complic
addit
sibl
also
sever
hypogammaglobulinemia
due
alter
process
nlink
glycansattach
immunoglobulin
ig
shorten
halflif
ig
molecul
circul
surprisingli
despit
sever
hypogammaglobulinemia
patient
clinic
evid
recurr
infect
interestingli
author
demonstr
cell
deriv
patient
reduc
abil
support
product
infect
multipl
envelop
virus
observ
suggest
alter
glycosyl
host
andor
viral
protein
confer
resist
viru
infect
may
least
part
explain
lack
recurr
viral
infect
cdgiib
patient
sever
humor
immun
defici
moreov
notion
fact
perfectli
consist
critic
role
er
glucosidas
ii
morphogenesi
infecti
entri
broadspectrum
envelop
virus
other
demonstr
last
three
decad
use
small
molecular
inhibitor
sirna
target
host
cellular
enzym
review
er
glucosidas
ii
sequenti
trim
three
termin
glucos
moieti
nlink
glycan
attach
nascent
glycoprotein
reaction
first
step
nlink
glycan
process
essenti
proper
fold
function
mani
glycoprotein
consist
known
function
defici
er
glucosidas
cdgiib
patient
result
retent
termin
triglucos
structur
nlink
glycan
ig
molecul
similarli
treatment
viral
infect
cell
er
glucosidas
inhibitor
repres
dnj
castanopermin
cast
deriv
ie
iminosugar
also
prevent
remov
three
termin
glucos
moieti
nlink
glycan
viral
envelop
glycoprotein
human
immunodefici
viru
hiv
spike
protein
sarscov
thu
far
document
er
glucosidas
inhibitor
suppress
infecti
virion
product
mani
envelop
virus
disrupt
nlink
glycan
process
envelop
glycoprotein
alter
nlink
glycan
structur
lead
misfold
degrad
viral
envelop
glycoprotein
although
suppress
er
glucosidas
activ
expect
impair
nlink
glycan
process
host
cellular
viral
glycoprotein
select
antivir
activ
glucosidas
inhibitor
like
due
fact
viral
glycoprotein
quantit
predomin
glycoprotein
made
infect
cell
thu
vulner
partial
inhibit
er
moreov
assembl
infecti
virion
particl
reli
coordin
interact
among
multipl
copi
envelop
glycoprotein
misfold
small
fraction
viral
glycoprotein
may
lead
failur
assembl
process
addit
suppress
viral
replic
defici
inhibit
er
glucosidas
may
also
modul
host
respons
viral
infect
alter
nlink
glycan
structur
either
viral
host
cellular
glycoprotein
particularli
interact
viral
glycoprotein
ctype
lectin
demonstr
play
import
role
viru
attach
host
cell
well
activ
cellular
innat
immun
respons
instanc
interact
oligosaccharid
dengu
viru
envelop
glycoprotein
ctype
lectin
receptor
macrophag
induc
strong
proinflammatori
cytokin
respons
lead
blood
vessel
leakag
hemorrhag
fever
symptom
furthermor
japanes
enceph
viru
induc
cytokin
respons
activ
also
essenti
viru
break
blood
brain
barrier
infect
central
nerv
system
thu
conceiv
reduc
virion
product
andor
alter
nlink
glycan
structur
viral
envelop
glycoprotein
er
glucosidas
inhibitor
may
inhibit
lectin
receptormedi
inflammatori
cytokin
respons
consequenti
allevi
viral
pathogenesi
addit
igg
interact
distinct
fc
receptor
requir
mani
aspect
immunolog
function
also
enhanc
infect
dengu
mani
virus
interestingli
select
igg
interact
differ
fc
receptor
modifi
glycan
structur
henc
glucosidas
inhibitorinduc
chang
nlink
glycan
igg
may
also
modifi
antibodymedi
pathogenesi
viral
infect
despit
great
promis
cellbas
studi
earlier
effort
develop
er
glucosidas
inhibitor
antivir
agent
treatment
three
major
chronic
viral
infect
includ
aid
hepat
b
hepat
c
fail
demonstr
signific
chang
et
antivir
ther
author
manuscript
avail
pmc
juli
antivir
efficaci
human
clinic
trial
anim
model
howev
antivir
efficaci
sever
iminosugarbas
er
glucosidas
ii
inhibitor
dengu
viru
japanes
enceph
viru
ebola
viru
marburg
viru
demonstr
recent
mice
review
clinic
trial
treatment
aid
hepat
c
treat
patient
develop
mild
moder
gastrointestin
disord
flatul
osmot
diarrhea
due
offtarget
inhibit
gut
disaccharidas
hydrolys
ingest
disaccharid
side
effect
usual
associ
oral
dose
larg
avoid
altern
rout
administr
altern
develop
iminosugar
prodrug
involv
convert
prodrug
biolog
activ
drug
within
circul
intracellular
compart
also
reduc
offtarget
effecthowev
major
concern
hosttarget
antivir
therapi
side
effect
due
ontarget
suppress
host
function
although
studi
anim
model
human
clinic
trail
suggest
iminosugar
glucosidas
inhibitor
gener
well
toler
mice
human
least
short
term
administr
tragic
clinic
present
cdgiib
patient
clearli
indic
longterm
suppress
er
glucosidas
andor
ii
potent
inhibitor
may
caus
signific
sideeffect
particularli
nerv
immun
system
moreov
unlik
chronic
viral
infect
longterm
potent
suppress
viral
replic
requir
achiev
benefici
clinic
efficaci
suppress
viremia
mere
log
earli
phase
acut
infect
dengu
hemorrhag
fever
demonstr
lifesav
henc
treatment
chronic
viral
infect
er
glucosidas
inhibitor
may
good
choic
due
potenti
side
effect
well
avail
potent
directact
antivir
drug
clinic
howev
broad
spectrum
antivir
activ
antiinflammatori
potenti
well
great
vivo
toler
short
term
administr
make
er
glucosidas
inhibitor
ideal
antivir
agent
acut
viral
diseas
particularli
treatment
viral
hemorrhag
fever
sever
respiratori
tract
viral
infect
viral
hemorrhag
fever
caus
mani
virus
four
differ
famili
includ
flavivirus
buyavirus
arenavirus
filovirus
server
respiratori
tract
viral
infect
also
caus
multipl
virus
three
distinct
famili
includ
influenza
virus
sever
paramyoxivirus
coronavirus
furthermor
influenza
virus
featur
season
variat
frequent
introduct
avainderiv
speci
etiolog
featur
make
develop
viral
specif
antivir
agent
treat
diseas
daunt
task
clinic
either
hemorrhag
fever
server
acut
respiratori
syndrom
caus
differ
virus
symptomat
similar
sometim
lifethreaten
short
time
window
therapeut
intervent
clinic
characterist
also
favor
therapi
virusspecif
antivir
agent
reli
timeconsum
etiolog
diagnos
contrast
broadspectrum
antivir
agent
perfectli
meet
clinic
need
fortun
virus
caus
two
clinic
syndrom
sensit
er
glucosidas
inhibitor
thu
potenti
efficaci
summari
sinc
alphainterferon
consist
effect
broadspectrum
hosttarget
antivir
agent
introduc
clinic
uniqu
clinic
manifest
cdgiib
patient
report
sadat
colleagu
greatli
boost
confid
develop
er
glucosidas
inhibitor
novel
broadspectrum
antivir
agent
particularli
virus
caus
lifethreaten
respiratori
tract
infect
hemorrhag
fever
effect
antivir
drug
still
press
need
